Research Papers:
IL35 expression in hepatocellular carcinoma cells is associated with tumor progression
PDF | Full Text | How to cite
Metrics: PDF 3339 views | Full Text 3734 views
Jun Long1, Hongyan Guo2, Shichang Cui3, Haiyan Zhang4, Xinmin Liu1, Danning Li1, Zimeng Han1, Linfeng Xi1, Wenyi Kou1, Jiangnan Xu1, Tao-Sheng Li5, Yaozhong Ding1
1Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, P.R. China
2Clinical Laboratory of Beijing Youan Hospital, Capital Medical University, Beijing, 100069, P.R. China
3Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, P.R. China
4Department of Cell Biology, Municipal Laboratory for Liver Protection and Regulation of Regeneration, Capital Medical University, Beijing, 100069, P.R. China
5Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan
Correspondence to:
Jun Long, email: [email protected]
Jiangnan Xu, email: [email protected]
Tao-Sheng Li, email: [email protected]
Yaozhong Ding, email: [email protected]
Keywords: IL-35, hepatocellular carcinoma, tumor progression, migration, invasion
Received: March 01, 2016 Accepted: June 03, 2016 Published: June 17, 2016
ABSTRACT
IL-35 has recently been demonstrated to play significant roles in the progression of various malignant tumors. We investigated the expression of IL-35 in hepatocellular carcinoma (HCC) and the regulatory mechanisms in HCC progression. Tissue microarray from 75 HCC patients revealed that IL-35 was primarily localized in the cytoplasm of cancer cells and peri-tumoral hepatocytes. Quantitative analysis showed that IL-35 expression was significantly lower in patients in the advanced stages than in the early stages. Significantly lower expression of IL-35 was also observed in HCC patients with higher histological grades, larger tumor size, positive microvascular invasion and lymph node/distant metastasis. IL-35 over-expression in HepG2 cells significantly upregulated HLA-ABC and CD95, reduced activities of MMP-2 and MMP-9, and decreased cell migration, invasion and colony formation capacities. Our data indicated that decreased expression of IL-35 in tumor tissues might contribute to the progression of HCC, and IL-35 may serve as a new therapeutic target for HCC.